PharmEasy Share Price 2023. PharmEasy is a consumer healthcare “super app” that provides consumers with on-demand, home delivered access to a wide range of prescription, OTC pharmaceutical, other consumer healthcare products, comprehensive diagnostic test services, and teleconsultations thereby serving their healthcare needs.
For buying unlisted shares of API Holdings (PharmEasy), please visit https://buysellunlistedshares.com/buy-api-holdings-pharmeasy-shares/
PharmEasy is India’s leading digital Healthcare Platform. It focuses on simplifying healthcare. The company provides services like Ordering Medicine, Healthcare Products and Diagnostics Tests.
PharmEasy, one of India’s leading platforms for healthcare solutions, aims to build a more holistic approach towards wellness for its customers in their journey of achieving good health.
API Holdings owns an umbrella of brands including PharmEasy, Thyrocare, Docon, Retailio, and Aknamed.
PharmEasy has evolved from being just a medicine providing platform to a wellness partner by building a sustainable healthcare ecosystem. This initiative is based on the belief that doing so would give its consumers 360-degree wellness support. It offers 1 lakh+ medicines and health products across various categories through its retail partners which are spread across the country.
API Holdings (Pharmeasy) Share Price Unlisted Details –
api holding share price has hit record high of about Rs 145 and record low of Rs 8 so far.
| Total Available Shares: | 10000+ |
| Face Value: | Re 1 Per Equity Share |
| ISIN: | INE0DJ201029 |
| Lot Size: | 500 Shares |
| Current Pharmeasy Share Price: | ₹ 13 per equity share |
API Holdings generates revenue from three segments –
Sale of Products: Sells pharma, over-the-counter, private label medical products, surgical products and consumables sourced from pharmaceutical companies or wholesalers to retailers, chemists and institutions.
Sale of Services: Derives revenue from sale of services from diagnostics, advertisement and lead generation for doctors by its B2B m
Other operating revenue: This includes providing last-mile delivery services to fulfilling orders on the platform, and lease of electronic medical records and practice management software and hardware to doctors.
The company provides health services ranging from teleconsultation to radiology tests to home delivery of medical products and devices.
In a bid to diversify its operations, the firm had acquired Thyrocare Technologies, India’s largest diagnostic test provider by volumes, in September.
Financial Performance of API Holdings (Figs in Rs Crore)
| Particulars | FY 2023 | FY 2022 | FY 2021 |
| Revenue | 6,705.26 | 5,728.82 | 2,335.27 |
| PAT | -2,277.30 | -3,992.50 | -641.34 |
| EPS | -1.56 | -7.28 | -2.67 |
API Holdings—the parent company of Pharmeasy, Docon, Thyrocare, and Retailio—logged a cumulative EBITDA of Rs 60 crore in the April to September period of 2023.
Company Background –
Founded in 2015 by Dharmil Sheth and Dhaval Shah, PharmEasy currently claims to connect more than 60,000 brick-and-mortar pharmacies and 4,000 doctors across 16,000 zip codes across the country. The start-up also claims to have served more than 20 million customers.
Latest api holdings share holders – api holdings shareholding pattern
| Shareholder Name | % to Holding | No. of shares |
| Naspers Ventures B. V. | 13.24 | 813,316,570 |
| MacRitchie Investments Pte. Ltd. | 11.93 | 732,516,290 |
| TPG Growth V SF Markets Pte. Ltd | 7.32 | 449,492,340 |
| Evermed Holdings Pte. Ltd. | 6.45 | 396,033,000 |
| Prasid Uno Family Trust through its trustee Surbhi Singh | 6.10 | 374,780,680 |
| CDPQ Private Equity Asia Pte. Ltd | 4.56 | 280,092,780 |
| Lightrock Growth Fund I SA, SICAV-RAIF, for and on behalf of Lightrock Global Fund | 3.88 | 238,229,320 |
| Bessemer India Capital Holdings II Ltd | 3.42 | 210,363,670 |
Active Pharmacies: 87,159
Prescribing doctors: 4,617
E-consultations conducted in FY21: 34 lakh
Digital prescriptions generated: 1.07 crore
Active wholesalers: 3,261
Registered users on PharmEasy: 2.5 crore
Valuation
The online pharmacy start-up was last valued at $5.6 billion (Rs 42,197.79 crore) in a Rs 2,635.22-crore pre-IPO round in October. It closed a $350 million pre-IPO funding round in October last year, taking its total fundraising in 2021 to nearly $1 billion. In February 2022, the company’s shares tanked to as low as INR 70 from INR 135-140 in the unlisted market. This might force the company to rework its IPO valuations, float issue on discount and even reconsider its IPO timeline.
To date, PharmEasy has raised over $1.2 billion in equity and debt funding and its last significant deal was the $600-million acquisition of diagnostics chain Thyrocare in June this year. PharmEasy was also the first unicorn in the online pharmacy start-up, achieving the coveted status in April 2021.
Based on API Holdings’ current suite of product and service offerings, the target market is expected to be $100 billion (Rs 7.5 lakh crore) by 2025, the DRHP said citing RedSeer Research.
Rights Issue
Pharmeasy Raises INR 750 Cr, Issues Convertible Notes
PharmEasy an online pharmacy has planned to raise INR 750 crore through convertible notes, Prosus Ventures and Temasek as well as its founders have subscribed to the issue for shares worth about Rs 200 crore.
Outlook
The company is expanding its products business in Semi Urban and Rural Markets across India. It is looking for deeper penetration into Tier-2 & Tier 3 cities.
PharmEasy continue to be in talks with marquee investors for anchor slots. Now, at what price it happens remains to be seen. Overall, the analysts are optimistic about the stock. In FY20, PharmEasy doubled its revenue to $83.45 Mn (INR 637 Cr). Founded in 2015 by Dharmil Sheth and Dr Dhaval Shah, PharmEasy merged with its investor entity, Ascent Health, to form API Holdings in 2019. This brought in three new cofounders – Siddharth Shah, Hardik Dedhia, and Harsh Parekh.
PharmEasy Files For Rs 6,250 Crore IPO – November 2021
Digital healthcare platform PharmEasy filed for an initial public offering (IPO) of up to Rs 6,250 crore ($842.43 million), becoming the latest startup in the country to pursue a domestic stock listing. API Holdings Ltd, PharmEasy’s parent, may also consider a further issue of equity shares via a private placement of up to Rs 1,250 crore, the company said in its draft red herring prospectus dated November 8.
PharmEasy intends to use the IPO proceeds to invest in three core areas, including marketing and promotional activities, supply chain infrastructure and fulfilment, and for upgrading its tech infrastructure.
Morgan Stanley India, BoFA Securities India, Kotak Mahindra Capital, JM Financial and Citigroup Global Markets India are appointed as lead bankers for the IPO.